CD86 and neoplasm: Specifically, eCPMV treated mice showed significantly elevated levels of leukocytes (CD45+ cells), CD11b+CD11c+ DCs, CD11bint-lowNK1.1+ NK cells, CD11b+Ly6G− monocytes, and CD11b+Ly6G+MHCII+CD86+ TINs compared with PBS-treated tumor bearing mice.